Supercharged t cells take on Hard-to-Treat lymphoma

NCT ID NCT00368082

Ongoing Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether specially trained immune cells (T cells) that are made resistant to a tumor's defense chemical can safely fight relapsed EBV-positive lymphoma. Eight patients will receive two injections of these modified cells, 14 days apart, at increasing doses. The main goal is to find the safest dose and check for side effects, while also seeing if the cells survive and shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically modified T cells (TGFbeta-resistant LMP-specific cytotoxic T lymphocytes)
What this could lead to: If it works, this could point toward a new treatment for relapsed EBV-positive lymphoma by helping immune cells survive and attack tumors.
What could go wrong: This is a very early Phase 1 trial with only 8 participants, so it is too small to prove effectiveness. The therapy may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV-POSITIVE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Epstein-Barr virus-associated lymphoproliferative disorder Hodgkins lymphoma lymphoma lymphoma, non-Hodgkin, familial nasopharyngeal type undifferentiated carcinoma non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN'S DISEASE LYMPHOMA LYMPHOMA, NON-HODGKIN RELAPSE

Contacts and locations

Locations

Houston Methodist Hospital

Houston, Texas, 77030, United States
Texas Childrens Hospital

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.